Literature DB >> 16971638

Does high-field MR imaging have an influence on the classification of patients with clinically isolated syndromes according to current diagnostic mr imaging criteria for multiple sclerosis?

M P Wattjes1, M Harzheim, C K Kuhl, J Gieseke, S Schmidt, L Klotz, T Klockgether, H H Schild, G G Lutterbey.   

Abstract

BACKGROUND AND
PURPOSE: Current MR imaging criteria for multiple sclerosis (MS) do not specify the magnetic field strength. The aim of this study was to investigate whether different MR imaging field strengths, specifically high-field MR imaging, have an impact on the classification of patients with clinically isolated syndromes suggestive of MS, according to MR imaging and diagnostic criteria.
METHODS: In a prospective intraindividual comparative study, we examined 40 patients with clinically isolated syndromes (CIS) consecutively with a 1.5 T and 3T MR imaging system, including axial sections of T2 turbo spin-echo, fluid-attenuated inversion recovery, and T1 spin-echo, before and after injection of gadolinium-diethylene-triaminepentaacetic acid. Constant resolution parameters were used for both field strengths. High-signal-intensity white matter lesions with a size of >3 mm were counted and categorized according to their anatomic location in infratentorial, callosal, juxtacortical, periventricular, and other white matter areas. Assessment of the fulfilled Barkhof MR imaging and McDonald diagnostic criteria was made separately for both field strengths in every patient.
RESULTS: Eleven patients fulfilled more MR imaging criteria at 3T. Two of these patients fulfilled the criterion of dissemination in space (DIS) according to the first definition of McDonald criteria, which is based on imaging criteria alone. Another patient had DIS only at 3T, according to the second definition of the McDonald criteria including CSF parameters.
CONCLUSION: MR field strength, specifically high-field MR imaging, has a substantial influence on the classification of patients with CIS according to imaging and a mild influence on the classification according diagnostic criteria for MS, leading to consequences for prognostic classification, imaging guidelines, and clinical trials.

Entities:  

Mesh:

Year:  2006        PMID: 16971638      PMCID: PMC8139807     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  24 in total

1.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Authors:  L D Jacobs; R W Beck; J H Simon; R P Kinkel; C M Brownscheidle; T J Murray; N A Simonian; P J Slasor; A W Sandrock
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

2.  Interscanner variation in brain MRI lesion load measurements in MS: implications for clinical trials.

Authors:  M Filippi; J H van Waesberghe; M A Horsfield; S Bressi; C Gasperini; T A Yousry; M L Gawne-Cain; S P Morrissey; M A Rocca; F Barkhof; G J Lycklama à Nijeholt; S Bastianello; D H Miller
Journal:  Neurology       Date:  1997-08       Impact factor: 9.910

3.  [The importance of magnetic field strength in the MR diagnosis of multiple sclerosis: a comparison of 0.5 and 1.5 T].

Authors:  W Schima; D Wimberger; B Schneider; R Stiglbauer; S Asenbaum; H Imhof
Journal:  Rofo       Date:  1993-04

4.  MR imaging field strength: prospective evaluation of the diagnostic accuracy of MR for diagnosis of multiple sclerosis at 0.5 and 1.5 T.

Authors:  D H Lee; A D Vellet; M Eliasziw; L Vidito; G C Ebers; G P Rice; L Hewett; S Dunlavy
Journal:  Radiology       Date:  1995-01       Impact factor: 11.105

5.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Authors:  G Comi; M Filippi; F Barkhof; L Durelli; G Edan; O Fernández; H Hartung; P Seeldrayers; P S Sørensen; M Rovaris; V Martinelli; O R Hommes
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

6.  Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.

Authors:  Frederik Barkhof; Mara Rocca; Gordon Francis; Jan-Hein T M Van Waesberghe; Bernard M J Uitdehaag; Otto R Hommes; Hans-Peter Hartung; Luca Durelli; Gilles Edan; Oscar Fernández; Pierette Seeldrayers; Per Sørensen; Simon Margrie; Marco Rovaris; Giancarlo Comi; Massimo Filippi
Journal:  Ann Neurol       Date:  2003-06       Impact factor: 10.422

7.  The effect of section thickness on MR lesion detection and quantification in multiple sclerosis.

Authors:  P D Molyneux; N Tubridy; G J Parker; G J Barker; D G MacManus; P S Tofts; I F Moseley; D H Miller
Journal:  AJNR Am J Neuroradiol       Date:  1998-10       Impact factor: 3.825

8.  MR identification of white matter abnormalities in multiple sclerosis: a comparison between 1.5 T and 4 T.

Authors:  M D Keiper; R I Grossman; J A Hirsch; L Bolinger; I L Ott; L J Mannon; C P Langlotz; D L Kolson
Journal:  AJNR Am J Neuroradiol       Date:  1998-09       Impact factor: 3.825

9.  Magnetic resonance imaging at 3.0 Tesla: challenges and advantages in clinical neurological imaging.

Authors:  Richard Frayne; Bradley G Goodyear; Peter Dickhoff; M Louis Lauzon; Robert J Sevick
Journal:  Invest Radiol       Date:  2003-07       Impact factor: 6.016

10.  Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla.

Authors:  Nancy L Sicotte; Rhonda R Voskuhl; Seth Bouvier; Rochelle Klutch; Mark S Cohen; John C Mazziotta
Journal:  Invest Radiol       Date:  2003-07       Impact factor: 6.016

View more
  29 in total

Review 1.  A systematic review of the utility of 1.5 versus 3 Tesla magnetic resonance brain imaging in clinical practice and research.

Authors:  Joanna M Wardlaw; Will Brindle; Ana M Casado; Kirsten Shuler; Moira Henderson; Brenda Thomas; Jennifer Macfarlane; Susana Muñoz Maniega; Katherine Lymer; Zoe Morris; Cyril Pernet; William Nailon; Trevor Ahearn; Abdul Nashirudeen Mumuni; Carlos Mugruza; John McLean; Goultchira Chakirova; Yuehui Terry Tao; Johanna Simpson; Andrew C Stanfield; Harriet Johnston; Jehill Parikh; Natalie A Royle; Janet De Wilde; Mark E Bastin; Nick Weir; Andrew Farrall; Maria C Valdes Hernandez
Journal:  Eur Radiol       Date:  2012-06-09       Impact factor: 5.315

2.  Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T.

Authors:  Mike P Wattjes; Götz G Lutterbey; Michael Harzheim; Jürgen Gieseke; Frank Träber; Luisa Klotz; Thomas Klockgether; Hans H Schild
Journal:  Eur Radiol       Date:  2006-04-29       Impact factor: 5.315

Review 3.  MRI in multiple sclerosis: what's inside the toolbox?

Authors:  Mohit Neema; James Stankiewicz; Ashish Arora; Zachary D Guss; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

4.  Lesion detectability on diffusion-weighted imaging in transient global amnesia: the influence of imaging timing and magnetic field strength.

Authors:  Inseon Ryoo; Jae Hyoung Kim; Sangyun Kim; Byung Se Choi; Cheolkyu Jung; Sung Il Hwang
Journal:  Neuroradiology       Date:  2011-05-21       Impact factor: 2.804

5.  Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study.

Authors:  J M Stankiewicz; M Neema; D C Alsop; B C Healy; A Arora; G J Buckle; T Chitnis; C R G Guttmann; D Hackney; R Bakshi
Journal:  J Neurol Sci       Date:  2009-04-15       Impact factor: 3.181

6.  High resolution MRI anatomy of the cat brain at 3 Tesla.

Authors:  Heather L Gray-Edwards; Nouha Salibi; Eleanor M Josephson; Judith A Hudson; Nancy R Cox; Ashley N Randle; Victoria J McCurdy; Allison M Bradbury; Diane U Wilson; Ronald J Beyers; Thomas S Denney; Douglas R Martin
Journal:  J Neurosci Methods       Date:  2014-02-10       Impact factor: 2.390

7.  Optimizing 3D FLAIR to detect MS lesions: pushing past factory settings for precise results.

Authors:  Augustin Lecler; C Bouzad; R Deschamps; F Maizeroi; J C Sadik; A Gueguen; O Gout; H Picard; J Savatovsky
Journal:  J Neurol       Date:  2019-08-01       Impact factor: 4.849

8.  Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis.

Authors:  Mike P Wattjes; Michael Harzheim; Götz G Lutterbey; Manuela Bogdanow; Stephan Schmidt; Hans H Schild; Frank Träber
Journal:  Neuroradiology       Date:  2007-11-03       Impact factor: 2.804

9.  Infratentorial lesion volume correlates with sensory functional system in multiple sclerosis patients: a 3.0-Tesla MRI study.

Authors:  C C Quattrocchi; A Cherubini; G Luccichenti; M G Grasso; U Nocentini; B Beomonte Zobel; U Sabatini
Journal:  Radiol Med       Date:  2009-12-16       Impact factor: 3.469

Review 10.  MRI in multiple sclerosis: current status and future prospects.

Authors:  Rohit Bakshi; Alan J Thompson; Maria A Rocca; Daniel Pelletier; Vincent Dousset; Frederik Barkhof; Matilde Inglese; Charles R G Guttmann; Mark A Horsfield; Massimo Filippi
Journal:  Lancet Neurol       Date:  2008-07       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.